

Recommended Dosages of Hepatitis B Vaccine & Hepatitis B Immune Globulin (HBIG) Including Hepatitis B Combination Vaccines

Hepatitis B Vaccine Recipients	Single-Antigen Vaccines				Combination Vaccines		
	Engerix-B® (GSK)		Recombivax HB® (Merck)		HEPLISAV-B®	Pediarix® (GSK)	Twinrix® (GSK)
	Pediatric Formulation	Adult Formulation	Pediatric/Adolescent Formulation	Adult Formulation		DTaP-HepB-IPV (6wks – 7yrs)	HepA-HepB (18 yrs & older)
Infants born to hepatitis B surface antigen (HBsAg) positive mothers*	10mcg (0.5mL) ¹ & (0.5mL) ² HBIG within 12 hours of birth		5mcg (0.5mL) ¹ & (0.5mL) ² HBIG within 12 hours of birth				
Infants born to mothers whose HBsAg status is unknown*	10mcg (0.5mL) ¹ within 12 hours of birth; (0.5mL) ² HBIG within 7 days if mom’s status remains unknown or sooner if HBsAg-positive		5mcg (0.5mL) ¹ within 12 hours of birth; (0.5mL) ² HBIG within 7 days if mom’s status remains unknown or sooner if HBsAg - positive				
Infants born to HBsAg negative mothers*	10mcg (0.5mL) ¹ within 24 hours of birth		5mcg (0.5mL) ¹ within 24 hours of birth				
Infants 6wks & older	10mcg (0.5mL)		5mcg(0.5mL)			10mcg (0.5mL) ^{1/3}	
Birth-19 years	10mcg (0.5mL)		5mcg(0.5mL)				
11-15 years⁴				10mcg (1mL) ⁴			
18 years & older					20mcg (0.5mL) ⁵		20mcg (1mL) ⁶
20 + years		20mcg (1mL)		10mcg (1mL)	20mcg (0.5mL) ⁵		20mcg (1mL) ⁶
Hemodialysis & other immuno-compromised persons	< 20 yrs	10mcg (0.5mL)		5mcg (0.5mL)			
	≥ 20 yrs		40mcg (2mL) ⁷		40mcg (1mL) ⁸		

For specific prescribing information, precautions, contraindications, and specific dialysis formulations, refer to product inserts.

*Newborns weighing less than 2000 grams see [Hepatitis B Vaccine and Hepatitis B Immune Globulin Administration for Infants](#)

¹**Hepatitis B vaccine** is recommended **within 12 hours** if mom is HBsAg-positive and **within 24 hours** of birth for medically stable babies born to HBsAg-negative mothers. This birth dose **MUST** be a single-antigen vaccine.

²**HBIG** (hepatitis B immune globulin) All infants born to HBsAg-positive women should receive (0.5mL) HBIG **within 12 hours of birth**. All susceptible contacts of an HBsAg-positive person should receive a (0.06 mL/kg) dose of HBIG, within 7 days of a blood exposure, or within 14 days of a sexual exposure, along with the hepatitis B vaccine series.

³**Pediarix®** (DTaP, hepatitis B and IPV) - GlaxoSmithKline (GSK)’s combination vaccine used as an alternative to single-antigens for administration at 2, 4 and 6 months of age. This combination vaccine is **NOT** to be given at birth. It may be given to any child between ages 6 weeks to 7 years of age for whom no antigen is contraindicated, and only as a primary series. (Primary series is considered first three doses of DTaP and IPV vaccines.) A 4-dose hepatitis B series is approved with a single-antigen dose of hepatitis B vaccine at birth followed by 3 additional doses of hepatitis B vaccine.

⁴**Adolescent 2-dose series** - Merck’s 2 dose adult Recombivax HB® (10mcg, 1 ml) used only for adolescents 11-15 years of age administered at 0 and 4-6 months apart. If this 2-dose regimen is used, **documentation must indicate adolescent received 2 adult (10mcg, 1ml) doses** of the Merck brand. If child starts hepatitis B series prior to age 11, between the ages of 11 and 15 with a hepatitis B vaccine other than adult formulation of Merck product, or completes series after age 15, a 3-dose series should be administered.

⁵**HEPLISAV-B** – Dynavax’s 2 dose series for persons 18 years of age and older at 0 & 1 month apart; can be used as a substitute in a 3-dose series with another brand of hepB vaccine.

⁶**Twinrix®** (hepatitis A and hepatitis B) – GSK’s combination vaccine used as an alternative to single-antigens for persons 18 years of age and older at 0, 1 & 6 months when neither antigen is contraindicated.

⁷**Engerix-B® dialysis formulation** is approved for adult hemodialysis and immunocompromised persons 20 years and older by using 2 x 20mcg/1mL at one site in one or two injections at 0, 1, 2 and 6 months.

⁸**Recombivax HB® dialysis formulation** is approved for adult hemodialysis and immunocompromised persons 20 years and older in a 3-dose series of 40mcg/1mL at 0, 1, and 6 months.